ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 42.71% | 39.19% | 36.20% | 10.23% | 10.17% |
| Total Depreciation and Amortization | -41.09% | -24.60% | -9.76% | -5.96% | -7.40% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -55.61% | -56.00% | -56.31% | -3.55% | -2.22% |
| Change in Net Operating Assets | 21.74% | 4.34% | -20.51% | -100.77% | 157.50% |
| Cash from Operations | 26.40% | 19.68% | 8.36% | -13.12% | 42.72% |
| Capital Expenditure | 10.23% | 10.23% | 76.76% | 95.87% | 95.43% |
| Sale of Property, Plant, and Equipment | -100.00% | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -100.00% | -100.00% |
| Cash from Investing | -184.95% | -99.11% | -99.24% | -99.05% | -99.18% |
| Total Debt Issued | -32.71% | -48.58% | -27.19% | 1,114.29% | 1,687.50% |
| Total Debt Repaid | 88.57% | 86.25% | 86.98% | 90.65% | -118.06% |
| Issuance of Common Stock | -71.86% | -9.30% | -9.30% | -23.24% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -27.99% | -7.51% | 26.39% | 1,513.24% | 1,090.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -39.21% | -91.67% | 25.54% | 100.57% | 98.40% |